UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000015583 |
|---|---|
| Receipt number | R000018106 |
| Scientific Title | Development and validation of mthods for genome and epigenome analysis of clinical samples using lung cancer tissue |
| Date of disclosure of the study information | 2014/11/01 |
| Last modified on | 2017/01/18 13:28:35 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Development and validation of mthods for genome and epigenome analysis of clinical samples using lung cancer tissue
Acronym
Development and validation of mthods for genome and epigenome analysis of clinical samples using lung cancer tissue
Scientific Title
Development and validation of mthods for genome and epigenome analysis of clinical samples using lung cancer tissue
Scientific Title:Acronym
Development and validation of mthods for genome and epigenome analysis of clinical samples using lung cancer tissue
Region
| Japan |
Condition
Condition
Lung cancer
Classification by specialty
| Not applicable |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Technical validation of genome and epigenome analysis methods developed for limited amount of samples, using clinical tissue samples.
Basic objectives2
Others
Basic objectives -Others
technical validation of chromatin immunoprecipitation-sequencing protocol.
Trial characteristics_1
Confirmatory
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
Production of chromatin immunoprecipitation data, genome variant call and information of chromatin regulation.
Key secondary outcomes
Aseesment results of data quality. Accuracy of nucleotide variant call by ChIPseq data.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Surgically removed tissue from lung cancer cases
Key exclusion criteria
Cases in which concent from patients was not obtained.
Target sample size
2
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masafumi Muratani |
Organization
Faculty of Medicine, University of Tsukuba
Division name
Genome Biology
Zip code
Address
1-1-1 Tennodai, Tsukuba, Ibaraki
TEL
029-853-7645
muratani@md.tsukuba.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masafumi Muratani |
Organization
Faculty of Medicine, University of Tsukuba
Division name
Genome Biology
Zip code
Address
1-1-1 Tennodai, Tsukuba, Ibaraki
TEL
029-853-7645
Homepage URL
muratani@md.tsukuba.ac.jp
Sponsor or person
Institute
Faculty of Medicine, University of Tsukuba
Institute
Department
Personal name
Funding Source
Organization
Faculty of Medicine, University of Tsukuba
Internal funding
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
筑波大学医学医療系（茨城県）において臨床組織検体を解析
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2014 | Year | 11 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 11 | Month | 04 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
| 2016 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2016 | Year | 03 | Month | 31 | Day |
Other
Other related information
Analysis of lung cancer tissue samples by chroamtin immunoprecipitation-sequencing.
Management information
Registered date
| 2014 | Year | 11 | Month | 01 | Day |
Last modified on
| 2017 | Year | 01 | Month | 18 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018106
